IQVIA Holdings Inc.(IQV)
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest News & Analysis
IQVIA's Booking Inflection Signals End of Clinical Research Trough
CEO Bousbib confirms decision timelines normalised, RFPs surging 20% YoY. Booking inflection signals end of clinical research trough.
IQVIA Q4 2024 Earnings: AI and International Growth Drive Performance
A detailed analysis reveals IQVIA’s robust Q4 2024 performance, driven by AI initiatives and expanding international revenue.
IQVIA: Analyzing Q4 Earnings, Sustainability Initiatives, and Growth Strategy
IQVIA releases 2024 Sustainability Report, Q4 2024 earnings surpass estimates, and AI integration drives growth. A comprehensive analysis of market impact and industry trends.
IQVIA: Navigating Market Trends and Charting a Growth Strategy in 2025
A comprehensive analysis of IQVIA Holdings Inc.'s latest market events, financial performance, and strategic initiatives for 2025.
IQVIA's Strategic Outlook: AI, Sustainability, and Q4 Earnings Analysis
IQVIA is demonstrating a strong focus on AI, sustainability, and strategic international growth. Recent financial performance and analyst outlooks suggest a positive future trajectory.
IQVIA: Sustainability, AI Innovation, and Market Performance Analysis
IQVIA navigates healthcare's complexities with AI, ESG focus, and strategic CFO insights, driving innovation and market leadership. A detailed analysis follows.
IQVIA (IQV): AI Innovation, Financial Performance, and Strategic Outlook
IQVIA (IQV) is leveraging AI, focusing on sustainability, and expanding globally. Key takeaways include strong financial performance and strategic initiatives.
IQVIA: Q4 Earnings, AI Innovation, and Market Outlook 2025
IQVIA (IQV) demonstrates strong financial performance and AI innovation. The company navigates market volatility with strategic initiatives for growth and leadership.
IQVIA: AI Innovation, Sustainability Focus, and Market Outlook
IQVIA is strategically positioned in the healthcare sector, leveraging AI, sustainability, and a diversified business model for growth. Recent achievements underscore its market leadership.
IQVIA Holdings Inc.: Strategic Insights and Market Analysis
IQVIA Holdings Inc. navigates a dynamic healthcare landscape with AI innovations and sustainability initiatives, facing regulatory and market challenges.
IQVIA (IQV): AI Innovation, Market Growth, and Financial Analysis
IQVIA (IQV) is navigating a complex healthcare landscape with strengths in AI innovation and a diversified client base, but faces liquidity and vaccination access challenges.
IQVIA (IQV): AI Innovation, Market Impact, and Healthcare Trends
IQVIA (IQV) faces a 5.57% stock drop amid AI innovation and market challenges. Analysis of AI strategies, global risks, financial health, and competitive positioning.
IQVIA Holdings Inc.: AI & RWE Drive Strategic Momentum
IQVIA leverages AI and real-world evidence to transform drug development, navigating market growth and strategic financing for future innovation.
IQVIA Holdings Inc. (IQV): AI, Data Privacy & Market Growth Analysis
IQVIA's recent MedTech Breakthrough Award and NVIDIA-powered AI agents highlight its pivotal role in healthcare analytics, navigating data privacy and market growth.
IQVIA Holdings Inc. AI Integration and Financial Strategy: Market Leadership Insights by Monexa AI
IQVIA advances AI in life sciences with NVIDIA partnership and $2B debt offering, enhancing clinical trials and oncology RWE amid strong financial fundamentals.
IQVIA Holdings Inc. Q2 2025 Analysis: Strategic Innovation Amidst Rising Competitive Pressure
IQVIA Holdings Inc. advances AI and RWE innovation to sustain growth amid competitive threats from agile rivals like Veeva, with solid financials ahead of Q2 earnings.
IQVIA (IQV): AI, RWE Oncology Growth & Financial Strategy
IQVIA Holdings Inc. is leveraging AI and strategic partnerships to drive growth in the expanding RWE oncology market, supported by recent financial maneuvers.
IQVIA Holdings Inc. Q2 2025 Earnings: AI Innovation Amid EBITDA Guidance Revision
IQVIA Q2 2025 earnings show 5.3% revenue growth driven by AI investments but reveal a cautious EBITDA guidance cut amid competitive pressures and strategic debt management.
IQVIA Holdings Inc. Q2 2025 Earnings and AI-Driven Growth Analysis | Monexa AI
Explore IQVIA's Q2 2025 earnings, AI integration in healthcare analytics, financial stability, and competitive positioning in the life sciences sector.
IQVIA's $2B Senior Notes and Strategic Moves Analyzed
IQVIA Holdings Inc. recently issued $2 billion in senior notes to manage debt and fund strategic growth. This analysis examines the move alongside key partnerships and RWE market trends.
IQVIA (IQV): Earnings Beat, Narrowed EBITDA Guidance and the Leverage of AI-Driven Analytics
IQVIA beat Q2 revenue and EPS but narrowed full‑year adjusted EBITDA to $3.75B–$3.825B; balance sheet shows heavy intangibles and net debt of **$12.45B**.